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Background: As part of the National Institute for Health and Care Excellence (NICE) single technology
appraisal (STA) process, independent Evidence Review Groups (ERGs) critically appraise the company
submission. During the critical appraisal process the ERG may undertake analyses to explore uncertainties
around the company’s model and their implications for decision-making. The ERG reports are a central
component of the evidence considered by the NICE Technology Appraisal Committees (ACs) in
their deliberations.
Objective: The aim of this research was to develop an understanding of the number and type of
exploratory analyses undertaken by the ERGs within the STA process and to understand how these
analyses are used by the NICE ACs in their decision-making.
Methods: The 100 most recently completed STAs with published guidance were selected for inclusion
in the analysis. The documents considered were ERG reports, clarification letters, the first appraisal
consultation document and the final appraisal determination. Over 400 documents were assessed in this
study. The categories of types of exploratory analyses included fixing errors, fixing violations, addressing
matters of judgement and the ERG-preferred base case. A content analysis of documents (documentary
analysis) was undertaken to identify and extract relevant data, and narrative synthesis was then used to
rationalise and present these data.
Results: The level and type of detail in ERG reports and clarification letters varied considerably. The vast
majority (93%) of ERG reports reported one or more exploratory analyses. The most frequently reported
type of analysis in these 93 ERG reports related to the category ‘matters of judgement’, which was
reported in 83 (89%) reports. The category ‘ERG base-case/preferred analysis’ was reported in 45 (48%)
reports, the category ‘fixing errors’ was reported in 33 (35%) reports and the category ‘fixing violations’
was reported in 17 (18%) reports. The exploratory analyses performed were the result of issues raised
by an ERG in its critique of the submitted economic evidence. These analyses had more influence on
recommendations earlier in the STA process than later on in the process.
Limitations: The descriptions of analyses undertaken were often highly specific to a particular STA and
could be inconsistent across ERG reports and thus difficult to interpret.
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Conclusions: Evidence Review Groups frequently conduct exploratory analyses to test or improve the
economic evaluations submitted by companies as part of the STA process. ERG exploratory analyses often
have an influence on the recommendations produced by the ACs.
Future work: More in-depth analysis is needed to understand how ERGs make decisions regarding which
exploratory analyses should be undertaken. More research is also needed to fully understand which types
of exploratory analyses are most useful to ACs in their decision-making.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Glossary
Adapted from the National Institute for Health and Care Excellence Technology Appraisal Process Guide
(National Institute for Health and Care Excellence. Guide to the Processes of Technology Appraisal. 2014.
URL: www.nice.org.uk/article/pmg19/chapter/foreword).
Appraisal Committee A standing advisory committee for the National Institute for Health and Care
Excellence. It includes people who work in the NHS, people representing patient and carer organisations,
lay members, and people from relevant academic disciplines and the pharmaceutical and medical
device industries.
Appraisal consultation document Sets out the Appraisal Committee’s preliminary recommendations to
the National Institute for Health and Care Excellence.
Final appraisal determination Sets out the Appraisal Committee’s final recommendations to the
National Institute for Health and Care Excellence on how the technology should be used in the NHS
in England.
Incremental cost-effectiveness ratio A statistic used to summarise cost-effectiveness. It is the ratio of
the difference in the mean costs of a technology compared with the next best alternative to the
differences in the mean outcomes.
Model An explicit mathematical framework that is used to represent clinical decision problems. It
incorporates evidence from a variety of sources so that the costs and health outcomes can be estimated.
Multiple technology appraisal The process designed to appraise single or multiple products, devices or
other technologies, with one or more related indications. The National Institute for Health and Care
Excellence seeks relevant evidence from several sources.
Single technology appraisal The process specifically designed to appraise a single product, device or
other technology, for a single indication. The process normally covers new technologies (typically, new
pharmaceutical products or new licensed indications) and enables the National Institute for Health and
Care Excellence to produce guidance soon after the technology is introduced in the UK. The National
Institute for Health and Care Excellence seeks relevant evidence from several sources. The company
submits the principal evidence.
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List of abbreviations
AC Appraisal Committee
ACD appraisal consultation document
BMJ British Medical Journal
CHE Centre for Health Economics
CRD Centre for Reviews and
Dissemination
CS company submission
ERG Evidence Review Group
FAD final appraisal determination
ICER incremental cost-effectiveness ratio
LRiG Liverpool Reviews and
Implementation Group
MTA multiple technology appraisal
NICE National Institute for Health and
Care Excellence
PAS Patient Access Scheme
QALY quality-adjusted life-year
ScHARR School of Health and Related
Research
STA single technology appraisal
TA technology appraisal
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Plain English summary
In the National Institute for Health and Care Excellence (NICE) single technology appraisal (STA) process,independent researchers called Evidence Review Groups (ERGs) assess a company evidence submission.
This assessment often includes exploring uncertainties in the information in the submission by conducting
alternative analyses. We aimed to explore the number and type of these explorations undertaken by the
ERGs. NICE requested that this work be carried out in order to better understand how ERGs conduct
alternative analyses.
We looked at more than 400 documents to determine what analyses had been done by the ERGs, the
reasons for these analyses and how this information was used. We separated the types of analyses into
categories and summarised the reasons for and content of the analyses. We also looked at how the NICE
Appraisal Committees (ACs) used this information in making their decisions.
We found that ERG reports had many differences in the amount and detail of their analyses. Over 93%
of ERG reports had at least one of these analyses, with an average number of eight analyses per report.
These analyses had more influence on recommendations earlier in the STA process than later on.
The ERGs frequently carry out analyses to better assess how uncertain information affects results. In this way,
they aim to improve and clarify the information submitted by companies. These analyses are used by the ACs
at NICE to help make their decisions on whether or not to recommend treatments.
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Scientific summary
Background
The National Institute for Health and Care Excellence (NICE) single technology appraisal (STA) process is
undertaken for a technology for a single indication. The process includes the production of a submission
by the manufacturer of the technology. One of the nine independent Evidence Review Groups (ERGs)
undertakes a critical appraisal of this submission. As part of the critical appraisal process the ERG may
undertake exploratory analyses to explore uncertainties around the company’s model and their implications
for decision-making. The number and type of exploratory analyses undertaken varies between appraisals.
The ERG reports are a central component of the evidence considered by the NICE Technology Appraisal
Committees (ACs) in their deliberations. The findings of the committee are used to produce the appraisal
consultation document (ACD) and, after further considerations and a consultation period, a final appraisal
determination (FAD) is produced, which results in NICE guidance.
Objectives
The aim of this research was to develop an understanding of the number and type of exploratory analyses
undertaken by the ERGs within the NICE STA process and to understand how these analyses are used by
the NICE ACs in their decision-making process. For the purpose of this research, an exploratory analysis
was defined as any additional analysis generating an incremental cost-effectiveness ratio (ICER) and
included in the ERG report section ‘Exploratory and sensitivity analyses undertaken by the ERG’. This is
most commonly reported as Section 6 of an ERG report, based on the suggested ERG report template.
The study aimed to address the following objectives:
1. to identify ERG reports that contain exploratory analyses conducted by the ERG, as defined above
2. to identify ERG approaches to exploratory analyses of economic evidence submitted by companies for
NICE STAs and to categorise these approaches by type of analysis performed
3. to identify data sources used for exploratory analyses undertaken by ERGs
4. to identify factors that influence or predict the extent of ERG exploratory analyses
5. to identify whether or not companies were provided with the opportunity to provide the analyses as
part of the clarification stage
6. to identify situations in which a committee requested the ERG to conduct additional analyses
7. to make an assessment of the degree to which the exploratory analyses influenced a committee’s
considerations and recommendations.
Methods
The 100 most recently completed STAs (from 2009) for which guidance has been published were selected
for inclusion in the analysis. The documents associated with the 100 STAs and used in data extraction were:
l ERG reports (unredacted versions, including confidential information used by the ACs)
l clarification letters and responses
l the first ACD issued (subsequent ACDs were not considered)
l the last FAD issued (where more than one FAD has been produced).
More than 400 documents were assessed in this study. Information on the number of AC meetings for
each STA was provided directly by NICE.
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A data extraction tool was developed and piloted to ensure usability and to standardise extraction.
The final categories of exploratory analyses were based on discussions with the project team and used
an existing relevant published taxonomy; the categories of types of exploratory analyses included
(i) fixing errors, (ii) fixing violations, (iii) addressing matters of judgement and (iv) the ERG-preferred base
case. All data extractions were double-checked. A narrative synthesis of the extracted data was performed,
summarising key data through text and tables to address the objectives. The mean number of exploratory
analyses per ERG report was calculated as well as the median. The key data used in the synthesis were then
reduced to whether a STA conducted more or fewer than the overall mean number of exploratory analyses.
Results
The level and type of detail in ERG reports and clarification letters varied considerably. The principal disease
areas covered by the STAs were cancer (44%), blood and the immune system conditions (11%),
cardiovascular conditions (10%) and musculoskeletal conditions (8%). Of the 100 STAs, 21% were
assessed by the AC using end-of-life criteria. The vast majority (93%) of ERG reports reported one or more
exploratory analyses with a range from 1 to 29 per report with an approximate mean of 8.5 analyses per
report and a median of 7 analyses per report. The most frequently reported type of analysis in the 93 ERG
reports that generated at least one exploratory analysis related to the category ‘matters of judgement’,
which was reported in 83 (89%) of reports. The category ‘ERG base-case/preferred analysis’ was reported
in 45 (48%), the category ‘fixing errors’ was reported in 33 (35%) and the category ‘fixing violations’ was
reported in 17 (18%). ERG reports often included more than one type of exploratory analysis. The principal
source of data used by the ERG was published literature.
The likelihood of an ERG performing eight or more exploratory analyses was not affected by the
company’s base-case ICER or disease area covered by the STA. The proportion of ERG reports with eight
or more analyses appears to be relatively stable over time, although the number of exploratory analyses did
vary by ERG.
Of the 93 STAs with at least one exploratory analysis, 65 (70%) ERG reports included at least one
exploratory analysis that was covered in the clarification letter to the company. Overall, 36% (287/798)
of the total exploratory analyses within the 93 reports were issues highlighted at the clarification stage.
Almost all exploratory analyses performed were the result of any issue raised by an ERG in its critique of
the submitted economic evidence, usually in the chapter in the ERG report preceding the section in which
the exploratory analyses were presented.
Appraisal consultation document recommendations were clearly influenced by one or more of the
mentioned ERG exploratory analyses in 55 out of the 76 STAs with ACDs (72%). This was reduced for
FADs, as FAD recommendations were clearly influenced by one or more of the mentioned ERG exploratory
analyses in 44 out of the 93 STAs with FADs (47%). The preferred ICERs reported in ACDs were 36%
from ERGs and 11% from companies, while in 9% of ACDs, ICERs from both ERGs and companies were
included or the ICERs from both were the same. This changed at FAD, where the preferred ICERs
were 27% from ERGs and 23% from companies, with 17% of FADs using some ICERs from ERGs and
some from companies.
Discussion
An ERG’s judgement relating to perceived uncertainties or possible variation in the evidence base and
model was the type of exploratory analysis appearing in the largest proportion of ERG reports. Rather than
simply generating a single alternative ICER, exploratory analyses were conducted to present a number of
scenario analyses.
SCIENTIFIC SUMMARY
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As the most recent 100 STAs with guidance issued were included in this analysis, current practice is
reflected. Extensive piloting and double-checking of data by experienced modellers helped to reduce
inconsistencies and inaccuracies in the data extraction. By using a descriptive synthesis method, the
likelihood of overstating relationships in the data was reduced.
Data extraction was difficult owing to the differences in the level and type of detail provided in the ERG
reports and clarification letters so that data extractors had to exercise interpretation of some of the data.
When grouping reports by indication, ICER or numbers of exploratory analyses, the numbers were too
small to evaluate relationships in the data using basic statistical tests in a meaningful manner.
Conclusions
Evidence Review Groups frequently conduct exploratory analyses to test or improve the economic
evaluations submitted by companies as part of the STA process. ERG exploratory analyses appear to often
influence the recommendations produced in the ACDs and FADs issued within the NICE STA process.
The influence appears to be greatest for ACDs and this influence is reduced by subsequent work between
the ACD and the FAD. For the 79% of STAs with no ACD, the company ICER was < £20,000 per
quality-adjusted life-year gained and the impact of the analyses was reduced. Caution should be used
when drawing conclusions from the evidence, especially concerning the generalisability of the findings.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background
Historical perspective
The National Institute for Health and Care Excellence (NICE) in the UK provides guidance and advice to
improve health and social care. NICE guidance contains evidence-based recommendations and includes
technology appraisals (TAs), which are recommendations on the use of new and existing medicines and
treatments within the NHS. The NICE single technology appraisal (STA) process is, in principle, undertaken
for a single technology for a single indication, although more than one comparator may be included. The
STA process began in 2005 and was introduced to enable the production of more rapid guidance than the
existing NICE multiple technology appraisal (MTA) process so that new products could be approved as
close to licensing as possible. Concerns were raised early on that although STAs resulted in more rapid
guidance, there remained uncertainty concerning the extent to which STAs adequately addressed the
specific decision problem under consideration.1 There have been considerable changes to the STA process
over time, such as the inclusion of scoping workshops, decision problem meetings, clarification letters and
end-of-life criteria.
Previous research found the STA process to be slower than initially anticipated, primarily because of events
outside NICE’s control,2 and that one-third of referred topics in the first 4 years of the STA process were
either suspended or terminated. In their study comparing the NICE STA process with the Scottish
Medicines Consortium process, Ford et al.3 found that, overall, the STA process reduced the average time
to publication compared with NICE MTAs (median 16.1 months compared with 22.8 months). However,
for cancer medications, the STA process took longer than the MTA process (25.2 months compared with
20.0 months). Barham4 also found that STAs took longer than anticipated, particularly for cancer drugs.
A more recent analysis by Casson et al.5 found STAs to be significantly faster than MTAs for all conditions.
NICE aims to issue guidance as close to marketing authorisation as is possible.
National Institute for Health Research single technology
appraisal process
Table 1 shows a brief description of the STA process.
The STA process is outlined in detail in NICE’s Guide to the Process of Technology Appraisal6 and includes
the production of an evidence submission by the company producing the technology. The company
submission (CS) to NICE forms the principal source of evidence for decision-making in the STA process.
The company is expected to follow the decision-analytic approaches as described in the Guide to the
Methods of Technology Appraisal7 and the submission is expected to contain an evaluation of the clinical
effectiveness and cost-effectiveness of the technology. Evidence Review Groups (ERGs) are charged with
the task of critically appraising the CS to identify strengths, weaknesses and gaps in the evidence
presented. Assessment by the ERG is conducted over an 8-week period. Templates exist for both the CS
and the ERG report. Early in the process a request for clarification, covering any issues that are unclear in
the submission, is made to the company, which is then given an opportunity to respond. As part of the
STA process, the ERGs also undertake exploratory analyses to explore uncertainties around the company’s
model and the implications of these for decision-making. It is the responsibility of the ERG to determine
what additional analyses are required and to undertake them. The ERG may also identify and correct
technical or programming errors that are identified. This critical appraisal of the CS and additional work
form the basis of the ERG’s report. The number and type of exploratory analyses undertaken varies
between appraisals, but they can contribute important evidence for consideration by an Appraisal
Committee (AC). These ERG reports are a central component of the evidence considered by the AC.
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Little guidance is given to ERGs on how to produce their reports. Some assessment of process has been
undertaken. For example, Wong et al.8 assessed approaches used by ERGs to critically appraise search
strategies within CSs. Previous research has highlighted issues with CSs that are particularly challenging to
the ERGs.9 Carroll et al.10 suggested that company STA submissions could be improved if attention were
paid to transparency in the reporting, conduct and justification of the review, and modelling processes and
analyses, as well as greater robustness in the choice of data in the model and closer adherence to the
scope or decision problem. Where this adherence is not possible, it was suggested that more detailed
justification of the choice of evidence or data is required. Kaltenthaler et al.11 also recommended the need
for clear and transparent reporting of CSs, and for a clear and concise rationale for the synthesis of clinical
data, the development of economic models and the assumptions used to develop models.
There are currently nine ERGs:
1. British Medical Journal (BMJ) Technology Assessment Group, BMJ Evidence Centre, BMJ Group
2. Centre for Reviews and Dissemination (CRD) and Centre for Health Economics (CHE), University of York
3. Health Economics Research Unit and Health Services Research Unit, University of Aberdeen
4. Kleijnen Systematic Reviews Ltd
5. Liverpool Reviews and Implementation Group (LRiG), University of Liverpool
6. Peninsula Technology Assessment Group, Peninsula Medical School, Universities of Exeter and Plymouth
7. School of Health and Related Research (ScHARR), University of Sheffield
8. Southampton Health Technology Assessment Centre, University of Southampton
9. Warwick Evidence, Warwick Medical School, University of Warwick.
An additional ERG, the West Midlands Health Technology Assessment Collaboration, undertook STAs
during the period 2005–10.
TABLE 1 Single technology appraisal process
STA process Weeks (approximately) since process start
Scope developed, sent out for consultation, discussed at scoping
workshop and final scope agreed
Draft scope in week 1, scoping workshop
weeks 7–9
Company discusses with NICE how the decision problem will be
addressed
Weeks (approximately) after decision
problem meeting and invitations sent
Company makes an evidence submission 9 (received by ERG)
ERG report developed: 2 weeks into the process the clarification letter is
sent to the company
17
First AC meeting to develop the ACD or FAD (if no ACD produced) 21
Second AC meeting to develop the FAD, if an ACD has been produced
at earlier AC meetings
29
After close of appeal period, NICE publishes guidance 38
AC, Appraisal Committee; ACD, appraisal consultation document; ERG, Evidence Review Group; FAD, final
appraisal determination.
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The ERG report, together with other evidence, is considered by one of four NICE ACs. ACs can make four
categories of recommendation: (1) recommended, (2) optimised (previously recommended under certain
circumstances, e.g. to a subgroup within the licence), (3) only in research and (4) not recommended. Each
appraisal may contain more than one recommendation. ‘Only in research’ recommendations are rare in
any TA process.12
A recommendation is considered provisional if the AC recommendation is not recommended, limitations
are recommended on the use of the technology or the company is asked to provide further clarification of
their evidence submission. If the recommendation is provisional, an appraisal consultation document (ACD)
is produced. At this stage, a ‘minded no’ preliminary recommendation may be issued, requiring more
information from companies before a final recommendation can be made. Following the publication of an
ACD, companies may submit additional evidence, which may include a Patient Access Scheme (PAS)
proposal, and the ERG may produce a report that assesses the impact of the PAS. A PAS may also be
submitted earlier on in the STA process. The AC, as part of its deliberations, considers the PAS as part of
the evidence for the appraisal.
The AC meets to consider the consultation comments received on the ACD and any additional evidence
produced. The ERG may be asked to critique any new evidence from the company. Final recommendations
are made in the form of the final appraisal determination (FAD). At the end of the appeal period, NICE
guidance is produced.
Aims and objectives
This study was commissioned by NICE and aims to investigate how ERGs undertake exploratory analyses
within the NICE STA process and how these analyses are used by the NICE ACs in their decision-making
process. For the purpose of this research, an exploratory analysis is defined as any additional analysis
generating an incremental cost-effectiveness ratio (ICER) and included in the ERG report section
‘Exploratory and sensitivity analyses undertaken by the ERG’. This is most commonly reported as Section 6
of an ERG report, if the suggested template is followed. This study aims to present an examination of the
experiences and outcomes related to instances in which ERGs have conducted additional exploratory
analysis and to examine what exploratory analysis have been done, and, where possible, why they were
done and what the outcome of the analyses were in terms of how they were managed by the AC and
used in the decision-making process. This is an under-researched area and this study was commissioned by
NICE to develop understanding of this aspect of the STA process. This research is of interest to all key
stakeholders in the STA process, including the ERGs, the pharmaceutical companies, AC members
and NICE.
The study seeks to address the following objectives:
1. to identify ERG reports that contain exploratory analyses conducted by the ERG, as defined above
2. to identify ERG approaches to exploratory analyses of economic evidence submitted by companies for
NICE STAs and to categorise these approaches by type of analysis performed
3. to identify data sources used for exploratory analyses undertaken by ERGs
4. to identify factors that influence or predict the extent of ERG exploratory analyses
5. to identify whether or not companies were provided with the opportunity to provide the analyses as
part of the clarification stage
6. to identify situations in which a committee requested the ERG to conduct additional analyses
7. to make an assessment of the degree to which the exploratory analyses influenced a committee’s
considerations and recommendations.
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Chapter 2 Methods
This research was jointly undertaken by teams at ScHARR at the University of Sheffield and CRD andCHE at the University of York. The objectives addressed by this research were initially identified by NICE.
A protocol was developed and peer reviewed and is available from the HTA website.13 A content analysis
of selected documents (documentary analysis) was undertaken to identify and extract relevant data, and
narrative synthesis was used to rationalise and present these data.
Selection of single technology appraisals
The 100 most recently completed STAs (since 2009) for which guidance has been published were selected
for inclusion in the analysis. It was considered among the team that 100 STAs represented the maximum
number of appraisals that could be considered within the time and resource constraints of the project and
that the 100 most recent appraisals would provide the most accurate reflection of current practice, as the
process has changed substantially since the initial introduction of STAs in 2005. A list of the STAs included
in this analysis is attached as Appendix 1.
All relevant documents for the 100 STAs were made available to the project team by NICE. The documents
used in the data extraction were:
l ERG reports (unredacted versions used by the ACs)
l clarification letters and responses
l the first ACD issued (subsequent ACDs were not considered)
l the last FAD issued (where more than one FAD has been produced).
Information on the number of AC meetings for each STA was provided directly by NICE. The research
required extraction of relevant data from more than 400 separate documents.
Data extraction
A sample data extraction template is attached as Appendix 2. The data extraction tool was formulated to
extract relevant data to address the project objectives.14 STA reports, clarification letters, ACDs and FADs
all have a basic, standard structure, which facilitated data extraction. The ERG reports have a specific
‘Exploratory’ or ‘Additional analyses’ section, usually Section 6, from which the data on exploratory analyses
were extracted. However, ERG reports and clarification letters and responses can vary greatly in their
descriptions of analysis and level of detail. Pilot data extraction was initially undertaken by four extractors
(AS, MH, SR and MR) on five STAs to develop and ensure the usability of the data extraction template. After
modifications were made to the extraction form, a further pilot data extraction exercise was undertaken
using three additional STAs in order to standardise extraction between the York and ScHARR teams. This
process produced the final agreed data extraction tool (see Appendix 3). The final categories of exploratory
analyses to be used in this study were created following this pilot process. They were based on discussions
with the whole project team and an existing relevant, published taxonomy.15 This approach was similar
to framework analysis techniques for developing an a priori framework for coding qualitative data.16
The categories were then defined in order to facilitate consistency of coding. The category ‘matters of
judgement’ was originally composed of three more specific categories: (1) uncertainty and evidence
variation, (2) alternative data and (3) ERG subjective judgement. However, it was found that the descriptions
of the analyses in the reports were often inadequate for ensuring that the information was being interpreted
and coded consistently into one of these categories. For this reason, a single, broader category of ‘matters of
judgement’ was created. The final four agreed categories of exploratory analysis are listed below (Table 2).
This simple scheme facilitated consistency of coding between data extractors.
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The seven parts of the data extraction tool are outlined in Table 3.
All data extractions were double-checked by two researchers: > 90% were double-checked by just two
team members (DHM and PT) in order to enhance the consistency of extraction and interpretation.
The York team extracted data from 24 STAs and the ScHARR team extracted data from 76 STAs. In order
to reduce possible bias in extraction, the York team extracted data from all of the ScHARR ERG reports
and the ScHARR team extracted data from all of the York CRD/CHE reports.
The level and type of detail provided in and across the ERG reports and clarification letters could be very
different, which made data extraction time-consuming, difficult and, at times, a matter of interpretation.
Despite efforts to simplify the data extraction and coding process (e.g. a small number of well-defined,
mutually exclusive categories of analysis), data extractors sometimes had to exercise interpretation for
some data, principally for whether exploratory analyses were prespecified or hinted at in clarification
letters. This issue of interpretation also affected the actual number of exploratory analyses undertaken by
an ERG and the influence of specific exploratory analyses on AC recommendations, in that in some
instances multiple analyses might be counted separately and in other instances they may be lumped
together as a single analysis. A typical example can found in the STA, Dabigatran Etexilate for the
Prevention of Stroke and Systemic Embolism in Atrial Fibrillation (TA249).17 In this case, the ERG conducted
many exploratory analyses, generating a range of ICERs, including an ERG-preferred base-case ICER of
£24,173 per quality-adjusted life-year (QALY). As part of these analyses, the ERG aimed to test the impact
of applying three different, but equally justified, sources of cost data for international normalised ratio
monitoring; this produced three only very slightly different ICERs. However, this was interpreted as only
one exploratory analysis, although it might arguably have been interpreted as three separate analyses. This
ERG report was considered to have a total of 14 exploratory analyses overall. In order to address issues of
interpretation such as this, the mean number of exploratory analyses was calculated. The key data used
in the synthesis were then reduced to whether a STA conducted more or fewer than the overall mean
number of exploratory analyses, and whether just ‘one or more’ exploratory analyses were explicitly cited
as having an influence on a recommendation. These arbitrary selections were made as a means of making
the most of the data to address the objectives of the project.
TABLE 2 Summary of categories of exploratory analysis
Category Definition
Fixing errors The ERG considered that something was unequivocally wrong in the company’s submitted model
Fixing violations The ERG considered that the NICE reference case, scope or best practice had not been adhered to for
one or more parameters or values, including missing out relevant comparators, and hence the model
is not fit for purpose
Matters of
judgement
The ERG did not consider that the submitted model was wrong as such, but amended the model by
conducting an analysis (often a sensitivity or threshold analysis) to test uncertainties within the
evidence or model, or because reasonable alternative assumptions could be applied. These could be
hypothetical or based on alternative data in the published literature or provided by a company
ERG-preferred
base case
The ERG conducted its own specific preferred base-case analysis. This might be the result of a series of
exploratory analyses. This base case might still not be ideal from the ERG’s perspective
METHODS
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Methods for analysis
A narrative synthesis was performed on the extracted data from the 100 ERG reports.18 This involved
summarising the key data through text and tables and then using narrative to highlight any potentially
important patterns or relationships in the data. This approach was taken because the large number of
reports and documents prevented meaningful, in-depth analysis of the text using qualitative methods,
but the numbers were not large enough to permit meaningful statistical analysis of the data. The synthesis
therefore described the incidence and frequency of exploratory analyses (objective 1); identified the types
of exploratory analyses performed by ERGs, as well as their data sources, where appropriate (objectives 2
and 3); explored relationships between key variables and the presence and frequency of exploratory
analyses (objective 4); described the role of exploratory analyses relating to the clarification process
(objective 5) and additional analyses post ACD (objective 6); and assessed the possible influence of
exploratory analyses on the recommendations of the ACs (objective 7). It was considered a priori that the
disease area and a cost-effectiveness threshold of £20,000 per QALY were the key variables most likely to
predict the incidence and frequency of exploratory analyses. This was because of the known impact of
disease area on other elements of STAs4 and the perceived importance of the £20,000 per QALY threshold
for NICE decision-making.19 An assessment was also made to identify any changes over time.
TABLE 3 Summary of data extraction tool
Section Details of fields
Project
objective
Basic characteristics l STA title
l ERG
l Company
l Disease area
l Prespecified subgroups or end-of-life criteria applied?
Extractors selected from a prespecified list of variables for most fields
4
Company’s base-case ICER(s) l What is the ICER for the single technology against the principal
comparator(s)?
l What are the ICERs for the technology against the next best
non-dominated or baseline comparators?
l What type of model was submitted?
4
Number and type of exploratory
analyses conducted by ERG
l See Table 2. Extractors selected from a prespecified list of categories
l Data extracted included the source(s) of alternative data,
where reported
1, 2, 3
Clarification letter and responses l Was the exploratory analysis mentioned or hinted at in the
clarification letter questions?
5
ACD l What was the preferred ICER and its source?
l What was the recommendation (prespecified list of variables)?
l Did the ACD mention one or more of the exploratory analyses and
was an ICER mentioned?
l Did one or more exploratory analysis influence the AC’s
recommendation (i.e. is the analysis or its ICER cited specifically in
relation to the recommendation)?
7
Additional work l Was additional work undertaken by the company and/or ERG
between the ACD and the FAD?
6
FAD l What was the preferred ICER and its source?
l What was the recommendation (prespecified list of variables)?
l Did the ACD mention one of more of the exploratory analyses and
was an ICER mentioned?
l Did one or more exploratory analysis influence the AC’s
recommendation (i.e. is the analysis or its ICER cited specifically in
relation to the recommendation)?
7
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In conducting the synthesis, the following assumptions were made:
l Every exploratory analysis had to have a separately reported ICER. If an analysis combined the results
of two or more exploratory analyses to calculate the third ICER, then this was considered to be a
further, separate analysis.
l The ICER taken for comparison was for the technology against its principal comparator or in the
principal scenario (its most likely use in clinical practice).
l When the base-case or preferred ICER reported by the company, ACD or FAD was a range or multiple
ICERs (e.g. for subgroups or scenarios), then the lowest ICER was used.
l If the technology was considered to be a cost-effective use of NHS resources, then it was deemed to be
so at a threshold of £20,000 per QALY gained.
l If the ACD or FAD simply stated that the technology was ‘dominating’, then it was assumed that it was
cost-effective at the threshold of £20,000 per QALY gained.
l If the ACD or FAD simply stated that the technology was ‘dominated’, then it was assumed that it was
not cost-effective at the threshold of £20,000 per QALY gained19 (although a technology could simply
be dominated by a very cost-effective comparator).
l The data on whether the analyses are mentioned by the ACD or FAD, or influenced their
recommendation, relate to the exploratory analyses described in the ERG report or a specific addendum
document (rather than any analyses conducted between the ACD and FAD).
l If any work was conducted by a company between an ACD and a FAD, it was assumed that it was
critiqued by the ERG as a standard procedure (explicit requests by an AC for an ERG to conduct such
work were rarely recorded in the ACD).
l Evidence of influence on a recommendation required a reference to an ERG’s exploratory analysis or
its ICER.
An example of the data extracted for a single STA, and used in the synthesis, is reproduced in Appendix 3.
METHODS
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Chapter 3 Results
General overview
Between September 2009 and September 2014, 100 STAs were undertaken by NICE that resulted in the
production of guidance and formed the basis for these analyses. In these 100 STAs, 40 different companies
submitted documents as part of the NICE STA process. The companies who were involved with the largest
number of submissions were Roche (n= 15), Novartis (n= 9), GlaxoSmithKline (n= 7), Bristol-Meyers Squibb
(n= 7) and Bayer (n= 6). The majority of companies made only one or two submissions (Table 4).
Ten ERGs conducted critical appraisals of these submissions. The principal ERGs were based at York
CRD/CHE (18 reports), LRiG (17 reports), ScHARR (13 reports), Aberdeen (11 reports) and Southampton
(10 reports). See Table 5 for the number of reports completed by each centre in this period.
The principal disease areas covered by the STAs were cancer (44%), blood and the immune system (11%),
cardiovascular conditions (10%) and musculoskeletal conditions (8%). The final scoping documents of
the majority of the STAs (66%) included pre-specified subgroups. In 21% of the STAs, end-of-life criteria
were considered by the AC (Tables 6 and 7).
TABLE 4 Companies making evidence submissions within STAs included in the analysis
Company Number of reports (n= 100)
1. Alimera Sciences 1
2. Alimta 1
3. Allergan Ltd 2
4. Amgen Inc. 2
5. Astellas Pharma 2
6. AstraZeneca 4
7. Bayer Healthcare 6
8. Biogen 1
9. Boehringer Ingelheim 3
10. Bristol-Meyers Squibb 7
11. Celgene 2
12. Cell Therapeutics Inc. 1
13. Eli Lilly and Company 5
14. Eliquis 1
15. Eisai Co. Ltd 1
16. Genzyme 2
17. GlaxoSmithKline 7
18. InterMune 1
continued
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TABLE 4 Companies making evidence submissions within STAs included in the analysis (continued )
Company Number of reports (n= 100)
19. Janssen Pharmaceutica 5
20. Laboratoires Servier 1
21. Movetis 1
22. MSD 2
23. Napp Pharmaceutical Group Ltd 1
24. Novartis Pharmaceuticals UK Ltd 9
25. Novo Nordisk 1
26. Otsuka Pharmaceutical 2
27. Pfizer 4
28. PharmaMar 2
29. Pharmaxis 1
30. Pierre Fabre 1
31. Roche 15
32. Sanofi-aventis 3
33. Savient Pharmaceuticals Inc 1
34. Schering-Plough 2
35. Stelara 1
36. Sucampo Pharma Europe 1
37. Takeda UK Ltd 2
38. The Medicines Company 1
39. ThromboGenics 1
40. UCB 1
MSD, Merck Sharp & Dohme.
The total is greater than 100 because six submissions were joint submission from more than one company.
TABLE 5 Evidence Review Groups responsible for producing reports within STAs included in the analysis
ERG Number of reports (n= 100)
Aberdeen 11
BMJ 8
Kleijnen Systematic Reviews Ltd 7
LRiG 17
PenTAG 4
ScHARR 13
Southampton 10
Warwick 5
West Midlands 7
York CRD/CHE 18
PenTAG, Peninsula Technology Assessment Group.
RESULTS
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Finally, it should be noted that for 19 STAs (19%) no ACD was produced: decisions were simply recorded
in the FAD. This means that some tables in the sections below do not report numbers for 100 STAs, but
rather have a denominator of 81.
Exploratory analyses
Evidence Review Group reports that contain exploratory analyses
The vast majority (93%) of ERG reports for the STA process conducted and reported one or more
exploratory analyses (Table 8): seven ERG reports did not contain any exploratory analysis that generated a
new ICER.20–26 In the 93 reports that did include an exploratory analysis, the number of analyses ranged
from 1 to 29, with an approximate mean of 8.5 analyses per report and a median of 7.
TABLE 6 Disease areas relevant to STAs included in the analysis
Disease area Number of reports (n= 100)
Blood and immune system 11
Cancer 44
Cardiovascular 10
Central nervous system 4
Digestive system 2
Endocrine, nutrition and metabolic 4
Eye 7
Infectious diseases 2
Mental health 2
Musculoskeletal 8
Respiratory 3
Therapeutic procedures 2
Urogenital 1
TABLE 7 Prespecified subgroups and end-of-life criteria assessed
Prespecified subgroups and end-of-life criteria Number of reportsa (n= 100)
With subgroups prespecified 66
With assessment for end-of-life criteria 21
a Some reports considered neither prespecified subgroups nor end-of-life criteria.
TABLE 8 Summary of numbers of exploratory analyses
Exploratory analyses Number
Proportion of reports with exploratory analyses 93/100 (93%)
Proportion of reports without exploratory analyses 7/100 (7%)
Number of exploratory analyses identified per report with analyses (mean)
(number of exploratory analyses/number of reports with analyses)
8.5 (798/93)
Number of exploratory analyses identified per report with analyses (range) 1–29
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Out of the 93 ERG reports with at least one exploratory analysis, a total of 40 (43%) included eight or
more such analyses. For the 10 ERGs undertaking STAs, the mean number of exploratory analyses per
report ranged from 2.3 (West Midlands) to 11.4 (ScHARR) (Table 9). It should be noted that no regression
analyses were performed to explore the relationship between the mean number of analyses per report by
ERG and other variables such as disease area and year, as well as other potentially influencing factors such
as complexity and perceived quality of CSs, owing to the limitations of the data.
It is clear from the histogram (Figure 1) that the vast majority of ERG reports conducted nine or fewer
analyses. Ten reports contained three or seven analyses, nine reports contained five analyses and six
reports contained eight analyses.
TABLE 9 Mean number of exploratory analyses by ERG
ERG
Number of analyses/number
of reports
Mean number of exploratory
analyses per report
ScHARR 148/13 11.4
BMJ 83/8 10.4
CRD 173/18 9.6
PenTAG 38/4 9.5
Southampton 91/10 9.1
Warwick 44/5 8.8
Aberdeen 72/11 6.5
LRiG 96/17 5.6
Kleijnen Systematic Reviews Ltd 37/7 5.3
West Midlands 16/7 2.3
Total and mean 798/100 8
PenTAG, Peninsula Technology Assessment Group.
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FIGURE 1 Distribution of exploratory analyses.
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Categories of Evidence Review Group approaches to exploratory analyses of
economic evidence
For the 93 ERG reports that generated at least one exploratory analysis, the type of analysis that appeared in the
largest proportion of reports was the category of ‘matters of judgement’; that is, the ERG considered there
to be uncertainty or possible variation regarding the evidence used to populate the model. At least one such
exploratory analysis was conducted in 89% of ERG reports. As a category of exploratory analysis, the calculation
of a new base case by an ERG appeared in more ERG reports (48%) than analyses which were concerned with
either fixing outright errors in the submitted models (35%) or fixing violations (18%) (Table 10).
Some examples of each of the categories are illustrated below based on extracts of text included in ERG reports.
Various categories 
Section 6.1: This section presents the results from additional cost-effectiveness analyses 
undertaken by the ERG. We begin by presenting a revised model correcting for a number of 
minor calculation errors and inconsistencies identified during the critique and examination  
of the Excel model provided as part of the MS. This revised model is then used to undertake 
a series of additional univariate sensitivity analyses to determine the robustness of the 
ICER results to alternative assumptions applied in the economic model. These alternative 
assumptions have been employed to address some of the remaining uncertainties and issues 
outlined in Section 5 of the ERG report and previously summarised in Table xxx. Finally, the 
ERG presents the results from a series of alternative scenarios. These scenarios are considered 
by the ERG to represent alternative and equally plausible ‘base-case’ approaches which 
explore the combined impact on the ICER of altering a range of alternative assumptions.  
TA20827 
Section 6: Where possible, the ERG has carried out sensitivity analyses to investigate the 
impact of alternative assumptions or parameters on the manufacturer’s cost-effectiveness 
results. Of these sensitivity analyses, the following have been combined to provide revised 
cost-effectiveness estimates: 
the use of utility data from chronic lymphocytic leukaemia patients receiving 3rd line therapy 
to inform the utility of PFS and PD (see Section 5.2.8); 
alternative estimates of disutility for anaemia, renal failure, weight loss and Grade 3 vomiting 
(see Section 5.2.8); 
the use of costs from BNF 64 rather than BNF 62 (see Section 5.2.9). 
In addition, scenario analyses of the ERG’s revised cost-effectiveness estimates have been 
carried out as follows: 
including costs associated with the treatment of leukopaenia and thrombocytopaenia (see 
Section 5.2.9); 
excluding potentially missing data from the calculation of average AE cost (5.2.9). 
Table xxx displays the results of the ERG’s sensitivity and scenario analyses on the 
manufacturer’s deterministic economic evaluation in the histologically confirmed aggressive 
B-cell patient population. The impact of the ERG’s sensitivity and scenario analyses on the 
manufacturer’s base case is presented in Appendix 16. 
TA30628 
Fixing errors 
ERG base 
case 
Matters of 
judgement 
Matters of 
judgement 
ERG base 
case 
Fixing 
violations 
(out-of-
date costs) 
TABLE 10 Proportion of reports with exploratory analyses for which the following categories were identified
Category Number of reports (%) (n= 93)
Matters of judgement 83 (89)
ERG base-case/preferred analysis 45 (48)
Fixing errors 33 (35)
Fixing violations 17 (18)
Numbers add up to more than 100% because an ERG report could include more than one type of analysis.
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Matters of judgement
Section 6.1 and 6.3: Opinion sought by the ERG suggested that it is far from certain that denosumab
will be administered in a primary care setting, and so some analysis was undertaken based on
assumptions that denosumab, zoledronate and ibandronate are administered entirely in a secondary
care setting. . . . Tables xxx have been provided to show how the ICERs for denosumab change by
subgroup using full secondary care costing assumptions for administration of denosumab and all the
secondary comparators
TA20429
Sections 6.4.2 and 6.4.3: The ERG noted in its critique of the manufacturer’s submission that some of
the assumptions in relation to treatment initiation and monitoring costs were not considered to be
sufficiently justified. The ERG examined a scenario which assumed that all treatments (as opposed to
just dronedarone) could be initiated in an outpatient setting. The resulting effect on the ICERs was
marginal and the overall conclusions on cost-effectiveness is not altered. . . . The ERG expressed some
concern that the utility values applied in the economic model potentially imply a higher estimate of
quality of life than that expected from the general UK population. In an attempt to address this issue,
the ERG adjusted the constant value of the regression model used to estimate utility values to ensure
that the values applied in the model do not exceed those of the general population. The adjustment
was made to the regression constant such that the utility value estimated for a 70 year old AF [atrial
fibrillation] male without any symptoms was reduced from 0.918 to 0.78, with the same adjustment
applied throughout the model for all patients. The ERG recognises that this is not the most appropriate
way to change the utility values but without access to the individual patient level data of the AFTER
study this was the best that the ERG could do to take account of the manufacturer’s potentially overly
optimistic estimates of overall QALYs. Table xxx presents the ICERs for the base case populations
incorporating the adjustment in HRQoL [health-related quality of life]. The implications for the
cost-effectiveness results were limited.
TA19730
Section 4.2.5: Pioglitazone costs
ISD Scotland prescription data notes the following balance between the three doses of pioglitazone in
the year to December 2010 . . . Ignoring the 15mg dose still suggests that a significant proportion of
patients may not titrate up to the maximum 45mg. Given a rough balance of 60:40 for 30mg: 45mg
would imply an average annual cost for pioglitazone of £487 compared to the £516 of the base case:
a reduction of £29. Over the initial 5 years of the modelling, on the basis of a discounted survival of
4.548 years in the pioglitazone arm this would be anticipated to reduce the pioglitazone total
discounted costs by £130. In itself, this would only worsen the cost effectiveness estimate for
once-weekly exenatide compared to pioglitazone from the £8,624 per QALY of the base case to
£9,357 per QALY.
TA24831
Evidence Review Group base-case/preferred analysis
Section 5.5.3: New model results were generated by the ERG to take account of each of the issues
previously identified (sections 5.5.2 and 5.5.3 above); the separate effect of each change is shown in
the upper section of Table xxx compared to the manufacturer’s submitted base case analysis. The most
influential amendments are the removal of a limit on the number of cycles of treatment any patient
could receive, and substitution of utility values based on the incidence of AEs [adverse events] reported
in the JMEN trial. The combined effect of these changes is to increase the incremental cost attributable
to use of pemetrexed by 35% as well as reducing the incremental QALYs gained by 2%, so that the
ICER increases from £33,732 to £47,239 per QALY gained.
TA19032
RESULTS
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Fixing errors
Section 5.5.3: A continuity correction is applied to models where a quantity is estimated at fixed time
points, but the entity of interest (e.g. cost or survival) is accrued over the period between the fixed
points. Relying only on values at either of the fixed points defining an interval may lead to systematic
over or under-estimation. . . . The correct approach is to use the area under the curve (AUC) from the
trial analysis unaltered, and then calculate ‘mid-cycle’ corrected estimates for the remainder of the
model duration derived from a parametric model. When this approach is applied to the manufacturer’s
base case, the incremental utility gain is reduced by 3.5%, and the ICER correspondingly increased to
£34,860 per QALY gained.
TA19032
Section 5.3.3: A minor error has been detected in calculating the proportion of patients assumed to
receive docetaxel and erlotinib in second-line therapy. When this is corrected the ICER for the
manufacturer’s base case rises slightly to £33,817 per QALY gained.
TA19032
Fixing violations
Addendum: Can an indication of the cost effectiveness of the first-line aripiprazole strategy compared
with a first-line risperidone strategy be provided using the estimated costs for risperidone (for
adolescent schizophrenia) and the manufacturer’s economic model? These issues were identified as
important by NICE as risperidone is generally reported as the current standard first line treatment in
adolescent schizophrenia, while the manufacturer’s economic model includes olanzapine as the main
comparator (due to inadequacies in the evidence base, discussed in the MS [manufacturer’s
submission] and the ERG report). Other comparators in the NICE scope were not modelled here.
A limitation of this modelling is that data on risperidone is from one RCT [randomised controlled trial]
only, not based on evidence from a systematic review.
TA21333 (e.g. failure to consider a key comparator in the scope)
Section 5.3.3: Post progression costs and utilities are calculated in the submitted model by
apportioning the overall mean survival between maintenance, second-line CTX [chemotherapy], BSC
[best supportive care] and terminal care phases. Since apportioning is carried out on the basis of
discounted overall survival estimates, and the costs are then discounted again, the post progression
costs are double discounted in the model. In addition, the estimation of QALYs relies on the same
discounted survival values and were similarly double discounted, so that incremental utilities are also
affected. The net consequence of correcting this error in the manufacturer’s base case is to increase
incremental costs by a small amount (for BSC costs only), but to increase incremental QALYs by about
5.5%, so that the ICER falls to £32,091 per QALY gained.
TA19032 (a base-case error)
Sources of evidence
It was difficult to ascertain the exact proportion of exploratory analyses that sourced data and to identify
those sources, but it was apparent that published literature, rather than the company or clinical experts,
was the principal source of data used by the ERGs, where a particular source was specified. Extractors
categorised particular sources of alternative data used for exploratory analyses in a total of 86 reports
(Table 11).
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Factors that might influence or predict the presence of
Evidence Review Group exploratory analyses
As noted above, this study aimed to test the possible influence of disease area, a cost-effectiveness
threshold of £20,000 per QALY gained and changes over time as the factors most likely to predict the
presence and numbers of exploratory analyses.
Disease area
Only five disease areas were the subjects of seven or more STAs. In this group, the blood and immune
system had the highest proportion of its STAs, with eight or more exploratory analyses (64%), and cancer,
the indication with the highest number of STAs, had the lowest (38%). However, the numbers were
generally too small to suggest that disease area might predict a higher than average number of exploratory
analyses (Table 12).
TABLE 11 Sources of alternative data
Source of data for exploratory analyses Apparent sources of data for exploratory analyses (n= 86)
Literature 69 (80%)
Manufacturer 33 (38%)
Clinical advisors 15 (17%)
Other 41 (48%)
Unclear 8 (9%)
Numbers add up to more than 100% because an ERG report could include more than one type of analysis.
TABLE 12 Number of reports by disease area with eight or more exploratory analyses
Disease area
Number of reports with
exploratory analyses (%) (n= 93)
Number of reports with eight or
more exploratory (%) analyses
Blood and immune system 11 (12) 7/11 (64)
Cancer 40 (43) 15/40 (38)
Cardiovascular 9 (10) 4/9 (40)
Central nervous system 4 (4) 2/4 (50)
Digestive system 2 (2) 0/2 (0)
Endocrine, nutrition and metabolic 3 (4) 1/3 (25)
Eye 7 (8) 4/7 (57)
Infectious diseases 2 (2) 1/2 (50)
Mental health 2 (2) 1/2 (50)
Musculoskeletal 7 (8) 4/7 (50)
Respiratory 3 (3) 0/3 (0)
Therapeutic procedures 2 (2) 1/2 (50)
Urogenital 1 (1) 0/1 (0)
RESULTS
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Company’s base-case incremental cost-effectiveness ratio and the
cost-effectiveness threshold of £20,000 per quality-adjusted life-year gained
Of the 93 companies’ submissions that attracted one or more exploratory analyses by an ERG, the
proportion submitting base-case ICERs that were cost-effective at the threshold of £20,000 per QALY was
almost the same as the proportion at or above this threshold. The likelihood of an ERG performing eight or
more exploratory analyses was not affected by the ICER: the proportion of reports that did so was
approximately the same (41% and 45%) (Table 13).
It is therefore the case that the presence of exploratory analyses, or of eight or more exploratory analyses,
is not obviously predicted either by the disease area covered by the STA or by a company’s base-case ICER
being less or more than the lower end of the cost-effectiveness threshold of < £20,000 per QALY.
Other factors that might determine the presence of exploratory analyses
The absence of exploratory analyses, or the presence of a relatively low number, could be caused by many
factors. It could be that the submitted model was considered fit for purpose (e.g. TA267:22 ERG report,
section 5.3, 122: ‘The ERG was satisfied with the estimates obtained from the manufacturer’s model.
Moreover, the sensitivity and subgroup analyses carried out by the manufacturer provided sufficient
assessment of any areas of uncertainty’). Equally, it could be caused by the submitted model being
perceived to be flawed to such a degree that additional analyses using the model and its data were
deemed to offer no value for decision-making (TA310:23 Section 6: ‘In view of the serious nature of the
major issues identified by the ERG, no attempt has been made to quantify the combined effect on the
ICER per QALY gained of correcting the minor issues identified below. The ERG takes the view that to do
so would give misleading credibility to the manufacturer’s ICERs per QALY gained. Instead, the minor
issues are described and the ERG’s preferred input values have been presented to allow comparison with
those used by the manufacturer.’).
The proportion of ERG reports with eight or more analyses appears to be relatively stable over time (from
2011 to 2014 the proportion of these as a percentage of all STAs in 1 year was always between 38% and
45%), which suggests that there have not been any particular developments that appear to influence the
frequency of exploratory analyses (Figure 2).
TABLE 13 Number of reports by company ICER with one or more exploratory analysis and eight or more
exploratory analyses
ICER Number of reports with one or more exploratory analyses
≤ £20,000 per QALY gained 44/93 (47%)
> £20,000 per QALY gained 49/93 (53%)
Number of reports with eight or more exploratory analyses
≤ £20,000 per QALY gained 18/44 (41%)
> £20,000 per QALY gained 22/49 (45%)
DOI: 10.3310/hta20260 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 26
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Kaltenthaler et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
17
Relationship between clarification requests, Evidence Review
Group critiques and exploratory analyses
After a company makes a submission, the ERG has only 2 weeks to read the submission and to request
clarification or data from the company. The data presented here consider whether or not any of the
exploratory analyses conducted by the ERG were specifically requested from the company but were not
provided; were requested but could not be completed by the company for a particular reason; were based
on data that were requested by the ERG in the clarification letter; or were ‘hinted at’ in the clarification
process (Table 14).
The relationship between an exploratory analysis and a request made in a clarification letter was rarely very
clear and might consist of little more than an analysis on an issue raised in the letter, without being
directly based on that request. It is clear, however, that, even with such possible indirect associations
between requests and the ERGs’ exploratory analyses, the majority of exploratory analyses performed by
ERGs (64%) were conducted for reasons other than the failure of the company to perform a specific,
requested analysis; rather, because the ERG identified other issues with the model, including any which
they had not had time to explore fully within the 2-week time frame for clarification.
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FIGURE 2 Single technology appraisals over time and proportions with eight or more exploratory analyses.
TABLE 14 Relationship between clarification letters and exploratory analyses
Clarification letter information
Proportion of clarification-letter-based
analyses
Proportion of reports with exploratory analyses that performed at least one
exploratory analysis that was covered in the clarification letter
65/93 (70%)
Clarification letter-based analyses as a proportion of the total exploratory
analyses within these 65 reports
287/653 (44%)
Clarification letter-based analyses as a proportion of the total exploratory
analyses within all 93 reports
287/798 (36%)
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It is also clear that almost every exploratory analysis performed was the result of an issue raised by an ERG
in its specific critiques of the submitted economic evaluation, usually in the chapter of the ERG report
preceding the section given over to the exploratory analyses. Examples of ERG reports that do not justify
their exploratory analyses in this way are very rare. For example, in TA196,34 the exploratory analysis
undertaken was to set the recurrence-free survival utility parameter equal to values of 0.95 and 0.90.
This does not appear to be mentioned or hinted at in the ERG’s critical appraisal.
Appraisal Committees and additional analyses
The majority of STAs involved additional work being performed between the production of the ACD and
the FAD. However, it was rare for the ACD to mention a request for an ERG to conduct further specific
analyses or critical appraisal. Where this did occur, it usually took place before the ACD. For example:
ERG Addendum: SHTAC were requested to provide additional analyses for the STA of aripiprazole for
the treatment of schizophrenia in adolescents (aged 15-17 years).
TA21333
ERG Addendum: This document provides further comment from the ERG regarding the indirect
comparisons of erlotinib and gefitinib presented by the manufacturer in the MS [manufacturer’s
submission]. It is provided in response to a NICE request arising from the pre-meeting
briefing discussions.
TA25835
It was more often the case that the ACD would request additional work from a company. For example:
ACD, 4.10: The Committee concluded that it was difficult to establish the most plausible ICER for this
treatment because sensitivity analyses to capture all preferred assumptions were not available.
However, the Committee concluded that the ICER may be within the range that is consistent with an
appropriate use of NHS resources. Therefore, because of these uncertainties, the Committee expects
the manufacturer to respond to this appraisal consultation document by addressing the remaining
uncertainties and by providing a revised cost-effectiveness analysis . . .
TA22636
ACD, 4.21: In summary, the Appraisal Committee could not assess whether gefitinib is a cost-effective
treatment option because it did not have sufficient information to assess the most plausible ICER for
gefitinib compared with standard platinum combination therapy or with pemetrexed and cisplatin.
Therefore the Appraisal Committee is minded not to recommend gefitinb for the treatment of locally
advanced or metastatic NSCLC [non-small-cell lung cancer]. It is recommending that clarification should
be sought from the manufacturer, including analyses that use alternative survival extrapolations and
application of hazard ratios, amended first-line chemotherapy costs and chemotherapy cycles,
alternative prevalence rates of EGFR-TK [epidermal growth factor receptor tyrosine kinase] mutations
and alternative assumptions about the cost of the EGFR-TK mutation tests.
TA19237
However, it was most often the case for there to be no specific request at all, but for a company to
conduct additional work or resubmit with a PAS in response to a negative recommendation in the ACD
(Table 15). It is often apparent in the FAD that this work was completed and also submitted for appraisal
by the ERG or the NICE Decision Support Unit.
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However, it should be noted that 19 out of 100 STAs did not produce an ACD; in these instances a FAD
was issued without the prior publication of an ACD. In all 19 of these FADs, the technology received a
positive recommendation. In the vast majority of these STAs, the company’s ICER in its original submission
was cost-effective at the threshold of £20,000 per QALY gained (15/19, 79%). These STAs also have a
smaller proportion of ERG reports (32%) with eight or more exploratory analyses than does the sample as
a whole (42%) (Table 16).
Table 17 shows the source of the ICERs preferred by the ACs as stated in the ACDs and FADs from the
STAs included in this analysis. Often more than one preferred ICER was presented in the documents.
The source of the preferred ICER was not always clear in the ACD and FAD. Of the 81 STAs with ACDs,
for the majority of cases either there was no preferred ICER (38%) or the ICERs presented by the ERG were
preferred by the AC (36%). In the 100 FADs, 27% of the preferred ICERs were from the ERG and 23%
were from the company. The number of preferred ICERs including both company and ERG increased from
7 (9%) at the ACD to 17 (17%) at the FAD. It should be noted that in 7 of the 100 STAs no ERG
exploratory analyses were undertaken.
TABLE 15 Work conducted between the ACD and the FAD
Details of STAs with ACDs Proportion satisfying criteria (%)
Proportion of STAs with additional work between the first ACDa and the FAD 60/81 (71)
Proportion of these STAs with a no or minded no recommendation in the ACD 58/60 (97)
Proportion of these STAs with an unspecified ICER in the ACD 20/60 (33)
Proportion of these STAs with a preferred ICER ≥ £20,000 per QALY gained in the
ACD
38/60 (63)
Proportion of these STAs with a preferred ICER < £20,000 per QALY gained in the
ACD
2b/60 (3)
a A total of 81/100 STAs had an ACD.
b One of these had a range of ICERs both below and above this £20,000 per QALYs threshold,29 and the second had ‘cost
savings of £400,000 per QALY’.38
TABLE 16 Single technology appraisals without an ACD
Details of STAs without an ACD Number of STAs (%) (n= 19)
Proportion of these STAs with a company ICER of ≤ £20,000 15 (79)
Proportion of these STAs with eight or more exploratory analyses 6 (32)
Proportion of these STAs with a positive recommendation in the FAD 19a (100)
a Only one STA had a recommendation optimised.39
TABLE 17 Source of preferred ICERs for ACDs and FADs
ERG Company Both ERG and company No preferred ICER Unclear
ACD (n= 81)
29 (36%) 9 (11%) 7 (9%) 31 (38%) 5 (6%)
FAD (n= 100)
27 (27%) 23 (23%) 17 (17%) 24 (24%) 9 (9%)
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Influence of the exploratory analyses on Appraisal Committees’
considerations and recommendations
Of the 100 STAs, 76 had one or more exploratory analysis performed by the ERG and also had an ACD. In
all but two of these STAs, the ACD made mention of at least one ERG exploratory analysis, and in a large
majority (72%) at least one such analysis appeared to influence the ACD recommendation (Table 18).
All 100 STAs produced a FAD and 93 also had at least one exploratory analysis. Eighty-seven of these
93 FADs (94%) mentioned one or more of the original exploratory analyses from the ERG reports, but
only 47% of STAs had final recommendations that appeared to be influenced by at least one of the
exploratory analyses.
A full list summary of the ACD and FAD decisions is given in Table 19. Technologies received positive
recommendations in < 18% of ACDs but subsequently received positive recommendations in 72%
of FADs.
It is worthy of note that almost half (48%) of the STAs that had an ACD that reported a recommendation
of no, only in research or minded no had moved to an outright recommendation or optimised
recommendation in the FAD. Only one-third of STAs did not see a positive recommendation (Table 20).
TABLE 18 Influence of exploratory analyses on the recommendations
Type of recommendation Number of reports (%)
ACD
ACD mentions one or more exploratory analysis 74/76 (97)
ACD recommendation is clearly influenced by one or more of the mentioned exploratory
analyses
55/76 (72)
FAD
FAD mentions one or more exploratory analysis 87/93 (94)
FAD recommendation is clearly influenced by one or more of the mentioned exploratory
analyses
44/93 (47)
TABLE 19 Decisions in ACDs and FADs
Decision Number of reports (%)
ACD (n= 81)
Recommended 10 (13)
Optimised 4 (5)
Minded no 19 (23)
No 48 (59)
FAD (n= 100)
Recommended 51 (51)
Optimised 21 (21)
No 28 (28)
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The ERG exploratory analyses apparently influenced the recommendation in a smaller proportion of FADs
(47%) than ACDs (72%). This can be explained by taking into account the work conducted between the
ACD and the FAD, reported in the section Appraisal Committees and additional analyses.
Patient Access Schemes
A total of 40 of the 100 STAs involved the submission of a PAS either as part of the original submission or
after the first ACD. The influence of the PAS on the final recommendations, when submitted as part of the
original appraisal, is unclear (Table 21). Almost half of companies that submitted a PAS did so from the
start of the process (17/40). Seven of the submissions did not have an ACD and received a positive
recommendation at the FAD. Of the remaining STAs, similar numbers received positive and negative
recommendations in the FAD.
However, when a PAS was submitted after the production of the ACD, it led to a positive change in
recommendation in 65% (15/23) of STAs (Table 22). This compares with 70% (7/10) when the PAS was
submitted as part of the original submission. The likelihood of a final negative recommendation appeared
to be slightly lower (24% vs. 35%) when a PAS was submitted as part of the original submission.
It is apparent that the ERG exploratory analyses are highly influential in the ACD but are necessarily
superseded by the additional work of companies and ERGs later, after the ACD, especially with a PAS.
However, Table 18 also suggests that the recommendations of almost half of the FADs (44%) were
apparently still influenced to some degree by one or more of the exploratory analyses performed by ERGs
in the earlier stages of the appraisal process and the ACD comments and recommendation will naturally
have influenced the FAD also.
TABLE 20 Changes of recommendation from ACD to FAD
ACD to FAD recommendation Number of reports (%) (n= 81)
No or minded no to recommended (including optimised) 39 (48)
No change positive recommendation (including from optimised to
full recommendation)
14 (17)
No change negative recommendation 28 (35)
TABLE 21 Patient Access Schemes submitted as part of the original submission
Number of STAs
with a PAS
Change from ACD
no to FAD positive
recommendation
Change from ACD
minded no to FAD
positive recommendation
No change positive
recommendation
(no ACD)
No change negative
recommendation
17/40 3/17 3/17 7/17 4/17
TABLE 22 Number with PAS submitted after ACD and before FAD
Number of STAs with
a PAS
Change from ACD no to FAD
positive recommendation
Change from ACD minded no to
FAD positive recommendation
No change negative
recommendation
23/40 11/23 4/23 8/23
RESULTS
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A summary of decisions and incremental
cost-effectiveness ratios
The perceived cost-effectiveness or otherwise of a technology is often considered to play a key role in
decisions. For this reason, a summary of the ICERs submitted by companies, and the preferred ICERs of
ACs, as outlined in the ACD and FAD, is tabulated below. It is apparent how many technologies appear to
be cost-effective at a threshold of £20,000 per QALY gained in the original CSs (Table 23), and how few
maintain that level of cost-effectiveness after appraisal and the production of the ACD.
The majority of ACDs record preferred or most plausible ICERs of > £20,000 per QALY gained or state that
there is no plausible ICER owing to uncertainties within the evidence and model (Table 24).
By the production of the FAD, 37% of the STAs had achieved a preferred ICER at this level and 43% of
the technologies were deemed to be cost-effective at a threshold of less than £30,000 per QALY
(Table 25).
TABLE 23 Company and ACD ICERs
Company base-case ICER to ACD-preferred ICER Number (%) of reports (n= 81)
No change (≤ £20,000) 9 (11)
From ≤ £20,000 to > £20,000 4 (5)
From ≤ £20,000 to ‘no preferred’ or ‘no plausible ICER’ 20 (25)
From ≥ £20,000 to ‘no preferred’ or ‘no plausible ICER’ 13 (16)
No change (> £20,000) 35 (43)
TABLE 24 Appraisals consultation document ICERs
ACD finding Number (%) of reports (n= 81)
With preferred ICER of ≤ £20,000 per QALY gained 9 (11)
With preferred ICER of > £20,000 per QALY gained 39 (48)
AC unable to specify a preferred ICER 33 (41)
TABLE 25 Final appraisal determination ICERs
FAD finding Number of reports (n= 100) Proportion (%) of recommendations
With preferred ICER of ≤ £20,000a 37 37/37 (100)
With preferred ICER of £20,000–30,000 6 6/6 (100)
With preferred ICER of > £30,000 36 17/36 (47)
AC did not specify a preferred ICERb 21 12/21 (57)
a Including range with at least one ICER of < £20,000 or an acknowledgement that the technology is cost-effective at
£20,000 threshold.
b Includes FADs without an ICER where the analysis was based on ‘costs’ alone.25,39
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All 43 STAs with a FAD-preferred ICER of < £30,000 per QALY gained received positive recommendations,
as did a further 29 in which the FAD did not specify a preferred ICER or reported one that was > £30,000
per QALY, yet the technology was still considered a cost-effective use of NHS resources. Therefore, 40%
(29/72) of recommendations were for technologies with an ICER that fell outside the perceived threshold
of cost-effectiveness, and only 8 of these 29 took end-of-life criteria into account. However, it is
noteworthy that 90% (19/21) of STAs that took into account end-of-life criteria (see Table 7) resulted in
a FAD with an unspecified ICER or one in excess of £30,000 per QALY.
The ICERs preferred by ACs were, therefore, often higher than the base-case ICER submitted by a
company, principally as a result of the exploratory analyses of an ERG. However, it is not the case that
these ERG analyses always generated a single, higher ICER than that submitted by the company. The
analyses would most often generate a number of different ICERs, with the aim of testing the findings
of the submission and providing useful information for the committees based on different thresholds or
scenarios. A typical example can be found in one STA, Dabigatran Etexilate for the Prevention of Stroke
and Systemic Embolism in Atrial Fibrillation (TA249).17 The CS reported a base-case ICER of £7940 per
QALY for dabigatran 150mg versus its principal comparator, warfarin. The ERG conducted 14 exploratory
analyses generating a range of ICERs, including an ERG-preferred base-case ICER of £24,173 per QALY.
The conclusion of the first AC was that the preferred ICER was between £6300 and £24,000 per QALY
and the final decision was that the most plausible ICER was < £20,000 per QALY. The company’s ICER
was, therefore, relevant and exploratory analyses generated the highest ICER, but the final decision was
made based on consideration of the range of ICERs.
RESULTS
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Chapter 4 Discussion
Statement of principal findings
Over 400 documents were analysed from the 100 STAs included in this analysis. The ERGs performed at
least one exploratory analysis in 93% of all STAs (objective 1). An ERG’s judgement relating to perceived
uncertainties or possible variation in the evidence base and model was the type of exploratory analysis
appearing in the largest proportion of ERG reports (objective 2). Where alternative data for an exploratory
analysis were identified, published literature such as trial evidence was the most frequent source
(objective 3).
As demonstrated by the frequency, number and type of analyses performed, ERG exploratory analyses
were not simply conducted to generate a single, alternative ICER, but rather presented a number of
scenario analyses, presumably with the intention of allowing an AC to decide which ICER they preferred.
The aim was to ensure that the AC had sufficient information in order to reach a decision. Where it was
deemed that the company had not provided this, it was the ERG who was responsible for undertaking
what they determined to be the most appropriate exploratory analyses. In essence, ERGs plug the gaps
in the evidence. They play in important role in reducing the uncertainty associated with the AC
decision-making process through their critical appraisal of the CS and undertaking exploratory analyses.
Not only do they test the company model, they aim to anticipate what information the AC will need in
order to make their decisions.
The incidence and frequency of ERG exploratory analyses do not appear to be related to any developments
in the process between 2009 and 2014, the disease area covered by the STA or the company’s base-case
ICER. There is no clear pattern to the presence or frequency of these analyses, although there does appear
to be a pattern in the mean number of analyses by ERG (objective 4). However, this association has not
been tested in a regression analysis to confirm whether or not the ERG centre is an independent predictor
of the number and extent of exploratory analyses. It might be affected by many variables, such as disease
area and year, as well as the complexity and perceived quality of CSs. Therefore, this finding should be
interpreted with caution and more research is needed to determine the relationship between ERG and the
number and extent of exploratory analyses. The number of exploratory analyses undertaken may also vary
according to the skills, experience and judgments of the ERGs and that of individuals within the ERGs. This
issue was not explored within this study.
The numbers of STAs undertaken by individual companies was small. Companies do not always produce
their submissions ‘in-house’ and may commission health economics consultancy organisations to produce
their submissions. This issue was not addressed in this study.
Fewer than half of the exploratory analyses were requested or hinted at in the clarification letters
submitted to companies (objective 5). This may be because of the clarification letter being submitted so
early on in the process that the ERG had not had time to develop a full understanding of the model and
what information may be needed. However, it was rare for an exploratory analysis not to be justified in a
preceding chapter of the ERG report in the critique of the submitted model.
For the majority (71%) of STAs, additional work was submitted by the company and ERG between the
ACD and the FAD. The ACD for almost all (97%) of these particular STAs made a ‘no’ or ‘minded no’
recommendation (objective 6). Approximately one-fifth of STAs did not produce an ACD; a large majority
of these STAs had a company ICER that was cost-effective at the threshold of £20,000 per QALY gained
and all received a positive recommendation in the FAD and required fewer exploratory analyses than the
sample as a whole.
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At least one of the exploratory analyses conducted and reported by an ERG is mentioned in 97% of ACDs
and had a clear influence on more than two-thirds of ACD recommendations. The influence of these
exploratory analyses is reduced in the FAD, although they still had a direct influence on the final
recommendations in almost half of STAs. The preferred ICERs reported in ACDs were 36% from ERGs,
11% from companies and 9% from both. This changed at the FAD, where the preferred ICERs were 27%
from ERGs, 23% from companies and 17% from both. The findings of work conducted by the company
and ERG between the ACD and the FAD appear to reduce the influence of the original ERG exploratory
analyses on the final recommendation, although the original analyses help to shape the ACs preferred
assumptions and inform further work (objective 7).
It cannot be assumed that the number of exploratory analyses is an indicator of the quality of a CS. As
stated above, with reference to STAs with no such analyses, this absence might be as a result of a model
being deemed by the ERG to be of either very good quality or very poor quality. If a model is considered to
be of very poor quality, the ERG may decide that it is pointless to undertake any exploratory analyses at all.
The type of analysis is more informative regarding quality. Analyses that are categorised as matters of
judgement might indicate an ERG exploring multiple scenarios relevant to an otherwise essentially sound
model and submission. This represented the principal type of analysis in this sample of STAs: 89% of
ERG reports with analyses contained at least one such analysis (see Table 10). However, if the ERG is
conducting analyses to fix errors or violations then this suggests that there were issues with the perceived
quality of the submitted model. In this sample, ERGs conducted at least one such analysis, respectively,
in 35% and 18% of STAs.
Strengths and limitations of the assessment
A strength of this research is that this was an analysis of the most recent 100 STAs, which offers a good
summary of current and recent practice. The development of a simple coding scheme, the extensive
piloting of the data extraction tool and the double-checking of all key data across the 100 STAs by at least
two experienced cost-effectiveness modellers reduced the likelihood of inconsistency and inaccuracy in the
data. In addition, the method of synthesis was principally descriptive, which reduces the likelihood of
overstating relationships in the data, and a reductive approach was taken to managing data that might be
affected by interpretation or by poor reporting in the original documents.
There are, however, some limitations in this research. The descriptions of analyses undertaken were often
highly specific to a particular STA and could be inconsistent across ERG reports and, thus, difficult to
interpret. The source of ICERs cited in ACDs and FADs could also be unclear or open to interpretation.
There are inherent weaknesses in using documentary analysis in that the researcher is able to analyse only
what has been reported. The level and type of detail provided in and across the ERG reports and
clarification letters could be very different, which made data extraction time-consuming, difficult and, at
times, a matter of interpretation. Documents varied greatly in their description of analysis and the level
of detail presented. Despite efforts to simplify the data extraction and coding process, data extractors
sometimes had to exercise interpretation for some data. It was often difficult to understand from the
documents alone the decision-making process that was being undertaken. In addition, the data did not
permit a deeper exploration of the nuances and complexities within the types of analyses (e.g. using the
fields types of models and nature of the implementation of the exploratory analysis, including
data sources).
Data extraction was undertaken by only two research teams, who between them had undertaken nearly
one-third of the STAs. Although this introduced a potential source of bias, it was overcome to some extent
by having neither team extract data from their own reports. In addition, the inside knowledge obtained
from working on so many STAs was crucially important in interpreting the data.
DISCUSSION
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It was not possible to report reliably exactly what proportion of the 100s of exploratory analyses was
actually mentioned in ACDs or FADs, or influenced their recommendations, and so this has been reduced
simply to whether ‘one or more’ exploratory analyses were mentioned or had an influence in any particular
STA. When grouping reports by disease area or ICER or numbers of exploratory analyses, the numbers
were too small to evaluate relationships in the data using basic statistical tests in a meaningful manner.
Further exploration, for example by assessing more STAs, might be able to determine whether or not
disease area is a predictor not only of the number of analyses but also of the type of analysis undertaken.
These limitations suggest that only cautious conclusions should be drawn from the evidence, especially
concerning the generalisability of any findings.
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Chapter 5 Recommendations
F rom the available evidence, it is not possible to specify the most useful type of ERG exploratory analysis,or the optimal number of analyses, for any particular STA, so ERGs can only continue to follow current
approaches, unless there are changes to the time frame or quality and breadth of the models submitted by
companies. It is important to recognise that exploratory analyses introduce greater transparency into the
evidence presented to the AC, providing a range of options from which the Committee can decide which
judgements it considers most reasonable. As such, the inclusion of exploratory analyses in the STA process
must be encouraged.
Any recommendations generated from this research are best developed in conjunction with all key
stakeholders including companies, NICE and the ERGs. The following are suggested recommendations
for consideration:
1. The ERGs spend a considerable amount of time identifying errors, inconsistencies and testing
assumptions in company models. In some instances the company provides verification of the model
already. However, where this is not the case, companies may wish to further explore the value of
additional peer review processes to identify such errors before submission.
2. Unequivocal errors in the CS could be listed and dealt with in a separate section of the ERG report,
distinct from other exploratory analyses undertaken by the ERG. The results from the correction of these
errors and no other changes could be presented in this section. If possible, these can be rechecked by
the company and agreement reached on the correct company ICER.
3. Where possible, companies should be asked at clarification letter stage to undertake exploratory
analyses identified as potentially important by the ERG and NICE at this early stage. However, the ERG
would still be required to undertake further exploratory analyses that are identified after the clarification
letter stage.
4. We recommend that a common terminology be used to describe the types of issues identified within
STA models and to describe the types of exploratory analyses undertaken by the ERGs. The taxonomy
used in this report may provide a useful starting point for ensuring consistency in the use of
such terminology.
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Chapter 6 Conclusions
Implications for service provision
The exploratory analyses undertaken by the ERGs appear to plug some of the gaps in the evidence
received from CSs, reduce uncertainty and support AC decision-making. They frequently influence both
ACD and FAD recommendations. Therefore, the use of ERG reports in the STA process appears to be
highly effective, in that all relevant information needed to reduce uncertainty is presented to the AC in a
timely and transparent manner, although the process can be resource- and time-intensive. It is often only
by the ERGs undertaking exploratory analyses that uncertainties in the evidence base are addressed and
ACs have enough evidence to make decisions on technologies. The number and extent of exploratory
analyses undertaken appear to be consistent over time and across disease areas. ERGs frequently
conduct exploratory analyses to test or use more appropriate parameters in the economic evaluations
submitted by companies as part of the STA process. ERG analyses are often highly influential in the first
recommendations of ACs. Their influence might then be superseded by later work (though they necessarily
do indirectly impact on the work conducted between an ACD and a FAD), but might still have an influence
on a recommendation in as many as half of all FADs. The provision of a longer period of reflection for
ERGs to identify all the possible issues or uncertainties with submitted evaluations might permit the
development of more comprehensive clarification letters and allow companies to perform more of the
required additional analyses.
Suggested research priorities
Future research priorities include:
l Undertaking a more in-depth analysis of how ERGs make decisions regarding which exploratory
analyses should be undertaken. This could take the form of a prospective qualitative study of a limited
number of STAs.
l Qualitative research with ACs members to determine when and which type of exploratory analyses are
most useful in their decision-making so that energies can be focused on these analyses.
l In-depth analysis of the category of ‘matters of judgement’. This could be done by prospectively
categorising the nature of the implementation of any exploratory analysis and the data sources used,
for example whether an analysis was based on different but equally valid assumptions or different but
equally valid sources of data. More in-depth analysis could be undertaken to explore how the presence
and extent of the exploratory analyses may vary according to the skills, experience and judgments of
the ERGs.
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Appendix 1 List of 100 single technology
appraisals
NICE TA
number Appraisal title
NICE document
ID number
TA181 Pemetrexed for the first-line treatment of non-small-cell lung cancer 35
TA182 Prasugrel for the treatment of acute coronary syndromes with percutaneous coronary
intervention
25
TA183 Topotecan for the treatment of recurrent and stage IVB cervical cancer 102
TA185 Trabectedin for the treatment of advanced soft tissue sarcoma 24
TA186 Certolizumab pegol for the treatment of rheumatoid arthritis 28
TA189 Sorafenib for the treatment of advanced hepatocellular carcinoma 22
TA190 Pemetrexed for the maintenance treatment of non-small-cell lung cancer 72
TA191 Capecitabine for the treatment of advanced gastric cancer 100
TA192 Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell
lung cancer
120
TA193 Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia 119
TA196 Imatinib for the adjuvant treatment of gastrointestinal stromal tumours 82
TA197 Dronedarone for the treatment of non-permanent atrial fibrillation 55
TA198 Tocilizumab for the treatment of rheumatoid arthritis 26
TA201 Omalizumab for the treatment of severe persistent allergic asthma in children
aged 6–11
123
TA202 Ofatumumab for the treatment of chronic lymphocytic leukaemia refractory to
fludarabine and alemtuzumab
126
TA203 Liraglutide for the treatment of type 2 diabetes mellitus 68
TA204 Denosumab for the prevention of osteoporotic fractures in postmenopausal women 61
TA205 Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic
purpura
13
TA208 Trastuzumab for the treatment of HER2-positive metastatic gastric cancer 59
TA211 Prucalopride for the treatment of chronic constipation in women 125
TA212 Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or
capecitabine for the treatment of metastatic colorectal cancer
47
TA213 Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years 122
TA214 Bevacizumab in combination with a taxane for the first-line treatment of metastatic
breast cancer
105
TA215 Pazopanib for the first-line treatment of advanced renal cell carcinoma 69
TA216 Bendamustine for the first-line treatment of chronic lymphocytic leukaemia 343
TA218 Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic
leukaemia and acute myeloid leukaemia
11
TA219 Everolimus for the second-line treatment of advanced renal cell carcinoma 71
TA220 Golimumab for the treatment of psoriatic arthritis 353
TA221 Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic
purpura
14
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NICE TA
number Appraisal title
NICE document
ID number
TA222 Trabectedin for the treatment of relapsed ovarian cancer 51
TA225 Golimumab for the treatment of rheumatoid arthritis after the failure of previous
disease-modifying anti-rheumatic drugs
19
TA226 Golimumab for the treatment of rheumatoid arthritis after the failure of previous
disease-modifying anti-rheumatic drugs
57
TA227 Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer 45
TA229 Dexamethasone intravitreal implant for the treatment of macular oedema secondary to
retinal vein occlusion
349
TA230 Bivalirudin for the treatment of ST-segment-elevation myocardial infarction 338
TA232 Retigabine for the adjunctive treatment of partial onset seizures in epilepsy 404
TA233 Golimumab for the treatment of ankylosing spondylitis 53
TA234 Abatacept for the treatment of rheumatoid arthritis after the failure of conventional
disease-modifying anti-rheumatic drugs
360
TA235 Mifamurtide for the treatment of osteosarcoma 36
TA236 Ticagrelor for the treatment of acute coronary syndromes 67
TA237 Ranibizumab for the treatment of diabetic macular oedema 369
TA238 Tocilizumab for the treatment of systemic juvenile idiopathic arthritis 318
TA239 Fulvestrant for the treatment of locally advanced or metastatic breast cancer 331
TA244 Roflumilast for the management of severe chronic obstructive pulmonary disease 341
TA245 Apixaban for the prevention of venous thromboembolism after total hip or knee
replacement in adults
307
TA248 Exenatide prolonged-release suspension for injection in combination with oral
antidiabetic therapy for the treatment of type 2 diabetes
336
TA249 Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial
fibrillation
94
TA250 Eribulin for the treatment of locally advanced or metastatic breast cancer 359
TA252 Telaprevir for the treatment of genotype 1 chronic hepatitis C 459
TA253 Boceprevir for the treatment of genotype 1 chronic hepatitis C 460
TA254 Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis 63
TA255 Cabazitaxel for hormone-refractory metastatic prostate cancer previously treated with
a docetaxel-containing regimen
400
TA256 Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial
fibrillation
420
TA258 Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK
mutation-positive non-small-cell lung cancer
473
TA259 Abiraterone for castration-resistant metastatic prostate cancer previously treated with a
docetaxel-containing regimen
465
TA260 Botulinum toxin type A for the prevention of headaches in adults with chronic migraine 462
TA261 Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent
deep vein thrombosis and pulmonary embolism
437
TA263 Bevacizumab in combination with capecitabine for the first-line treatment of metastatic
breast cancer
54
TA264 Alteplase for treating acute ischaemic stroke 536
TA266 Mannitol dry powder for inhalation for treating cystic fibrosis 85
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NICE TA
number Appraisal title
NICE document
ID number
TA267 Ivabradine for treating chronic heart failure 484
TA268 Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma 73
TA269 Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive
malignant melanoma
498
TA271 Fluocinolone acetonide intravitreal implant for the treatment of chronic diabetic
macular oedema after an inadequate response to prior therapy
419
TA272 Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of
the urothelial tract
320
TA275 Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial
fibrillation
500
TA282 Pirfenidone for treating idiopathic pulmonary fibrosis 334
TA283 Ranibizumab for treating visual impairment caused by macular oedema secondary to
retinal vein occlusion
328
TA284 Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of
advanced ovarian cancer
435
TA285 Bevacizumab in combination with gemcitabine and carboplatin for treating the first
recurrence of platinum-sensitive advanced ovarian cancer
490
TA287 Bevacizumab in combination with gemcitabine and carboplatin for treating the first
recurrence of platinum-sensitive advanced ovarian cancer
569
TA288 Dapagliflozin in combination therapy for treating type 2 diabetes 427
TA289 Ruxolitinib for disease-related splenomegaly or symptoms in adults with myelofibrosis 510
TA290 Mirabegron for treating symptoms of overactive bladder 542
TA291 Pegloticase for treating severe debilitating chronic tophaceous gout 521
TA292 Aripiprazole for treating moderate to severe manic episodes in adolescents with
bipolar I disorder
305
TA293 Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura 589
TA294 Aflibercept solution for injection for treating wet age-related macular degeneration 519
TA295 Everolimus in combination with exemestane for treating advanced HER2-negative
hormone-receptor-positive breast cancer after endocrine therapy
538
TA296 Crizotinib for previously treated non-small-cell lung cancer associated with an
anaplastic lymphoma kinase fusion gene
499
TA297 Ocriplasmin for treating vitreomacular traction 544
TA298 Ranibizumab for treating choroidal neovascularisation associated with pathological
myopia
555
TA299 Bosutinib for previously treated chronic myeloid leukaemia 495
TA303 Teriflunomide for treating relapsing–remitting multiple sclerosis 548
TA305 Aflibercept for treating visual impairment caused by macular oedema secondary to
central retinal vein occlusion
578
TA306 Pixantrone monotherapy for treating multiply relapsed or refractory aggressive
non-Hodgkin's B-cell lymphoma
414
TA307 Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating
metastatic colorectal cancer that has progressed following prior oxaliplatin-based
chemotherapy
514
TA308 Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic
antibody-associated vasculitis
567
DOI: 10.3310/hta20260 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 26
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Kaltenthaler et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
41
NICE TA
number Appraisal title
NICE document
ID number
TA309 Pemetrexed maintenance treatment following induction therapy with pemetrexed and
cisplatin for non-squamous non-small-cell lung cancer
489
TA310 Afatinib for treating epidermal growth factor receptor mutation-positive locally
advanced or metastatic non-small-cell lung cancer
556
TA311 Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy
and autologous stem cell transplantation
610
TA312 Alemtuzumab for treating relapsing-remitting multiple sclerosis 539
TA313 Ustekinumab for treating active psoriatic arthritis 607
TA315 Canagliflozin in combination therapy for treating type 2 diabetes 554
TA316 Enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with
a docetaxel-containing regimen
600
TA318 Lubiprostone for treating chronic idiopathic constipation 725
TA319 Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma 74
TA320 Dimethyl fumarate for treating relapsing-remitting multiple sclerosis 585
TA321 Dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive
melanoma
605
TA322 Lenalidomide for treating myelodysplastic syndromes associated with an isolated
deletion 5q cytogenetic abnormality
480
ID, identification.
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Appendix 2 Sample data extraction template
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Appendix 3 Example data extraction
Data extraction was undertaken from NICE TA 190.32
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